Sunday - June 2, 2024
GlaxoSmithKline: Positive RUBY Phase III Data Show Potential for Jemperli (dostarlimab) Combinations in More Patients With Primary Advanced or Recurrent Endometrial Cancer
April 17, 2024
LONDON, England, April 17 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 16, 2024:

GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer. These data were presented today in a late-bre . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products